Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PRF TechnologiesPRFX -2.38%22 Equity-to-Asset is 0.83 as of Jun. 2026, which is 9% above its 10-year median of 0.76. GuruFocus rates PRFX with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 1,006 Drug Manufacturers companies, PRF Technologies ranks better than 84.69% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. PRF Technologies's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $15.87 Mil. PRF Technologies's Total Assets for the quarter that ended in Jun. 2026 was $19.09 Mil.
Therefore, PRF Technologies's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.83.
The historical rank and industry rank for PRF Technologies's Equity-to-Asset or its related term are showing as below:
PRFX'
s Equity-to-Asset Range Over the Past 10 Years
Min: -55.03 Med: 0.76 Max: 0.96
Current: 0.83
During the past 8 years, the highest Equity to Asset Ratio of PRF Technologies was 0.96. The lowest was -55.03. And the median was 0.76.
PRFX's Equity-to-Asset is ranked better than 84.69% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs PRFX: 0.83
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
PRF Technologies Equity-to-Asset Related Terms
PRF Technologies Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for PRF Technologies's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRFX vs CTTH, UPC, AKAN: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PRF Technologies's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PRF Technologies Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PRF Technologies's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where PRF Technologies's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
PRF Technologies's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRF Technologies (PRFX) has a Equity-to-Asset of 0.83 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on PRF Technologies and its competitors. This is near median its historical median of 0.76. According to the industry distribution chart, PRF Technologies ranks #154 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 15.3%.
Is PRF Technologies' Equity-to-Asset too high?
PRF Technologies' current Equity-to-Asset of 0.83 is near median its 10-year median of 0.76. The Drug Manufacturers industry median Equity-to-Asset is 0.60. PRF Technologies' value of 0.83 is 38.3% above this industry median. Based on the distribution chart, PRF Technologies ranks #154 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PRF Technologies has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does PRF Technologies' Equity-to-Asset compare to CTTH and UPC?
According to the Drug Manufacturers industry distribution chart, PRF Technologies ranks #154 out of 1006 companies for Equity-to-Asset. This places PRF Technologies in the top 15% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.60. PRF Technologies' value of 0.83 is 38.3% above this benchmark. While the company's 10-year median is 0.76 vs. the industry median of 0.60, PRF Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PRF Technologies's current Equity-to-Asset of 0.83 is 38.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on PRF Technologies and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PRF Technologies's current Equity-to-Asset is 0.83, which is near median its own 10-year median of 0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PRF Technologies stock overvalued right now?
PRF Technologies (PRFX) has a current Equity-to-Asset of 0.83. The current Equity-to-Asset is 0.83, which is near median its 10-year median of 0.76 and 38.3% above the Drug Manufacturers industry median of 0.60. PRF Technologies' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For PRF Technologies (PRFX), the current Equity-to-Asset is 0.83 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.
22GF Score
Get the complete analysis for PRFX
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRFX has been successfully added to your 
